Download PDF
Semin Thromb Hemost 2001; 27(4): 357-372
DOI: 10.1055/s-2001-16889
Copyright © 2001 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Production and Clinical Development of a Hansenula polymorpha-Derived PEGylated Hirudin

George C. Avgerinos1 , Brian G. Turner1 , Kenneth J. Gorelick1 , Adam Papendieck2 , Ulrike Weydemann2 , Gerd Gellissen2
  • 1Abbott Bioresearch Center, Worcester, Massachusetts
  • 2Rhein Biotech GmbH, Düsseldorf, Germany
Further Information

Publication History

Publication Date:
31 August 2001 (online)

    Permissions and Reprints

ABSTRACT

This article describes the expression of the hirudin gene heterologously in the methylotrophic yeast Hansenula polymorpha, the establishment of an industrial-scale production process and the subsequent clinical development of polyethylene glycol (PEG)-hirudin. PEGylation increases the molecular weight of hirudin, thereby reducing its kidney filtration rate and immunogenicity and increasing its half-life in the circulation.

KEYWORD

Hirudin - PEG-hirudin - Hansenula polymorpha, manufacturing - clinical development

REFERENCES

  • 1 Haycraft J B. Über die Einwirkung eines Sekretes des Blutegels auf die Gerinnbarkeit des Blutes.  Naunyn Schmiedebergs. Arch Exp Pathol Pharmacol . 1884;  18 209-217
    PubMedSearch in Google Scholar
  • 2 Seemüller U, Dodt J, Fink E, Fritz H. Proteinase inhibitors of the leech Hirudo medicinalis (hirudins, bdellins, eglins). In: Barett A, Salversen G, eds. Proteinase Inhibitors Amsterdam: Elsevier 1986: 337-359
    Search in Google Scholar
  • 3 Schweden J, Eckes P, Hornberger W, Subkowski T. Conjugates of hirudin and lipophilic compounds.1999; U.S  Patent # 5,919,762.
    PubMed
  • 4 Grossenbacher H, Chang J Y, Maerki W. Cloning, preparation, and thrombin inhibitor activity of high-molecular-weight desulfatohirudin mutein.  1997; U.S. Patent #5, 661,001.
    PubMed
  • 5 Kurfuerst M, Ruebsamen K, Schmied B. Preparation of hirudin-polyalkylene glycol complexes.  1997; U.S. Patent #5,663,141.
    PubMed
  • 6 Roggenkamp R O, Hansen H, Eckart M, Janowicz Z A, Hollenberg C P. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors.  Mol Gen Genet . 1986;  202 302-308
    PubMedSearch in Google Scholar
  • 7 Gellissen G. Heterologous protein production in methylotrophic yeasts.  Appl Microbiol Biotechnol . 2000;  54 741-750
    CrossrefPubMedSearch in Google Scholar
  • 8 Schaefer S, Piontek M, Ahn S-J. Recombinant hepatitis B vaccines-characterization of the viral disease and vaccine production in the methylotrophic yeast, Hansenula polymorpha In: Dembowsky K, Stadler P, eds. Novel Therapeutic Proteins. Weinheim: Wiley-VCH; 2001: 245-274
    Search in Google Scholar
  • 9 Mayer A F, Hellmuth K, Schlieker H. An expression system matures: a highly efficient and cost-effective process for phytase production by recombinant strains of Hansenula polymorpha Biotechnol Bioengineering .  1998;  63 373-381
    PubMedSearch in Google Scholar
  • 10 Gellissen G, Hollenberg C P. Hansenula In: Robinson RK, Batt CA, Patel PD, eds. Encyclopedia of Food Microbiology. San Diego, CA: Academic Press; 2000: 976-982
    Search in Google Scholar
  • 11 Gellissen G, Hollenberg C P, Janowicz Z A. Gene expression in methylotrophic yeasts. In: Smith A, ed. Gene Expression in Recombinant Microorganisms New York: Marcel Dekker 1994: 195-239
    Search in Google Scholar
  • 12 Ledeboer A M, Edens L, Maat J. Molecular cloning and characterization of a gene coding for methanol oxidase in Hansenula polymorpha Nucleic Acids Res .  1985;  13 3063-3082
    PubMedSearch in Google Scholar
  • 13 van Dijk R, Faber K N, Kiel J K W A, Veenhuis M, van der Klei I. The methylotrophic yeast Hansenula polymorpha: a versatile cell factory.  Enzyme Microb Tech . 2000;  26 793-800
    CrossrefPubMedSearch in Google Scholar
  • 14 Brake A J, Merryweather J P, Coit D G. α-Factor-directed synthesis and secretion of mature foreign proteins in Saccharomyces cerevisiae Proc Natl Acad Sci USA .  1984;  81 4612-4616
    PubMedSearch in Google Scholar
  • 15 Waters M G, Evans E A, Blobel G. Prepro a-factor has a cleavable signal sequence.  J Biol Chem . 1988;  263 6209-6214
    PubMedSearch in Google Scholar
  • 16 Dohmen R J, Strasser A WM, Dahlems U, Hollenberg C P. Cloning of the Schwanniomyces occidentalis glucoamylase gene (GAM1) and its expression in Saccharomyces cerevisiae Gene .  1990;  95 111-121
    PubMedSearch in Google Scholar
  • 17 Weidemann W, Gromoll J, Keller R. Cloning and sequence analysis of cDNA for precursor of a crustacean hyperglycemic hormone.  FEBS Lett . 1989;  257 31-34
    CrossrefPubMedSearch in Google Scholar
  • 18 Weydemann U, Keup P, Piontek M. High-level secretion of hirudin by Hansenula polymorpha-authentic processing of three different preprohirudins.  Appl Microbiol Biotechnol . 1995;  44 377-385
    CrossrefPubMedSearch in Google Scholar
  • 19 Dohmen R J, Strasser A WM, Höner C B, Hollenberg C P. An efficient transformation procedure enabling long-term storage of competent cells of various yeast genera.  Yeast . 1991;  7 691-692
    CrossrefPubMedSearch in Google Scholar
  • 20 Griesbach U, Stürzebecher J, Markwardt F. Assay of hirudin in plasma using a chromogenic thrombin substrate.  Thromb Res . 1985;  37 347-350
    CrossrefPubMedSearch in Google Scholar
  • 21 Roggenkamp R, Hansen H, Eckart M, Janowicz Z A, Hollenberg C P. Transformation of the methylotrophic yeast Hansenula polymorpha by autonomous replication and integration vectors.  Mol Gen Genet . 1986;  202 302-308
    PubMedSearch in Google Scholar
  • 22 Esslinger H U, Greger G, Lassmann A, Maurer R. General tolerability and effects on clotting parameters after single i.v. and s.c. bolus administration of recombinant hirudin (LU 52369) in man.  Thromb Haemost . 1991;  65 1291 Abstract 
    PubMedSearch in Google Scholar
  • 23 Markwardt F, Nowak G, Stürzebecher J. Pharmacokinetics and anticoagulant effect of hirudin in man.  Thromb Haemost . 1984;  52 160-163
    PubMedSearch in Google Scholar
  • 24 Bowen S, Tare N, Inoue T. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein.  Exp Hematol . 1999;  27 425-432
    CrossrefPubMedSearch in Google Scholar
  • 25 Ho D H, Brown N S, Yen A. Clinical pharmacology of polyethylene glycol-L-asparaginase.  Drug Metab Dispos . 1986;  14 349-352
    PubMedSearch in Google Scholar
  • 26 Tsutsumi Y, Kihira T, Tsunoda S. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation.  J Pharmacol Exp Ther . 1996;  278 1006-1011
    PubMedSearch in Google Scholar
  • 27 Tsutsumi Y, Tsunoda S, Kamada H. PEGylation of interleukin-6 effectively increases its thrombopoietic potency.  Thromb Haemost . 1997;  77 168-173
    PubMedSearch in Google Scholar
  • 28 Esslinger H U, Haas S, Maurer R. Pharmacodynamic and safety results of PEG-hirudin in healthy volunteers.  Thromb Haemost . 1997;  77 911-919
    PubMedSearch in Google Scholar
  • 29 Esslinger H U, Merz M. Safety and anticoagulant effects of intravenous PEG-hirudin in elderly and healthy young subjects.  Eur J Clin Pharmacol . 1997;  52(Suppl) 83 Abstract 
    PubMedSearch in Google Scholar
  • 30 Nowak G, Bucha E, Goock T, Thieler H, Markwardt F. Pharmacology of r-hirudin in renal impairment.  Thromb Res . 1992;  66 707-715
    CrossrefPubMedSearch in Google Scholar
  • 31 Vanholder R, Camez A, Veys N. Pharmacokinetics of recombinant hirudin in hemodialyzed end-stage renal failure patients.  Thromb Haemost . 1997;  77 650-655
    PubMedSearch in Google Scholar
  • 32 Pöschel K, Bucha E, Esslinger H U. Pharmacodynamics and pharmacokinetics of polyethylene glycol-hirudin in patients with chronic renal failure.  Kidney Int . 2000;  58 2478-2484
    CrossrefPubMedSearch in Google Scholar
  • 33 Fareed J, Callas D, Hoppensteadt D A, Walenga J M, Bick R L. Antithrombin agents as anticoagulants and antithrombotics.  Implications in drug development. Curr Con Thromb . 1998;  82 569-586
    PubMedSearch in Google Scholar
  • 34 Ruebsamen K, Hornberger W. Prevention of early reocclusion after thrombolysis of copper coil-induced thrombi in the canine carotid artery: comparison of PEG-hirudin and unfractionated heparin.  Thromb Haemost . 1996;  76 105-110
    PubMedSearch in Google Scholar
  • 35 Ruebsamen K, Kirchengast M. Thrombin inhibition and intracoronary thrombus formation: effect of polyethylene glycol-coupled hirudin in the stenosed, locally injured canine coronary artery.  Coron Artery Dis . 1998;  9 35-42
    PubMedSearch in Google Scholar
  • 36 Buchwald A B, Hammerschmidt S, Stevens J. Inhibition of neointimal proliferation after coronary angioplasty by low-molecular-weight heparin (Clivarine) and polyethyleneglycol-hirudin.  J Cardiovasc Pharmacol . 1996;  28 481-487
    CrossrefPubMedSearch in Google Scholar
  • 37 Unterberg C, Stevens J, Meyer T. Adventitial proliferation after coronary stent angioplasty: temporal pattern and response to antithrombotic intervention.  Eur Heart J . 1997;  18(Suppl) 503 Abstract 
    PubMedSearch in Google Scholar
  • 38 Bossavy J P, Sakariassen K S, Rubsamen K. Comparison of the antithrombotic effect of PEG-hirudin and heparin in a human ex vivo model of arterial thrombosis.  Arterioscler Thromb Vasc Biol . 1999;  19 1348-1353
    PubMedSearch in Google Scholar
  • 39 Hoppensteadt D, Walenga J M, Bacher P. Comparative efficacy of recombinant hirudin and PEG-hirudin in a dog model of hemodialysis.  Ann Hematol . 2000;  79(Suppl 1) 89 Abstract 
    PubMedSearch in Google Scholar
  • 40 Mustafa M UA, Kadr H, Hooper J, Kemp M, Stephens J D. PEG-hirudin compared with unfractionated heparin reduces the burden of silent ischemia in patients with acute coronary syndromes.  Heart . 2000;  83(Suppl 1) 55 Abstract 
    PubMedSearch in Google Scholar
  • 41 Steg P G, Petrauskiene B, Lopez-Sendon J. A randomized trial of safety and efficacy of long-acting PEG-hirudin in patients with unstable angina and non-Q-wave myocardial infarction.  Eur Heart J . 1998;  19(Suppl) 50 Abstract 
    PubMedSearch in Google Scholar
  • 42 Montalescot G, Collet J P, Lison L. Effects of various anticoagulant treatments on von Willebrand factor release in unstable angina.  J Am Coll Cardiol . 2000;  36 110-114
    CrossrefPubMedSearch in Google Scholar
  • 43 van Wyk V, Badenhorst P N, Luus H G, Kotze H F. A comparison between the use of recombinant hirudin and heparin during hemodialysis.  Kidney Int . 1995;  48 1338-1343
    PubMedSearch in Google Scholar
  • 44 Esslinger H U, Bucha E, Pöschel K. Pharmokinetics of PEG-hirudin in subjects with various degrees of renal function.  Ann Hemotol . 1998;  76(Suppl 1) A97
    PubMedSearch in Google Scholar